<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682357</url>
  </required_header>
  <id_info>
    <org_study_id>11199</org_study_id>
    <nct_id>NCT00682357</nct_id>
  </id_info>
  <brief_title>Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis</brief_title>
  <official_title>Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Lindsley, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral and nasal steroids may enhance osteoporosis by suppressing bone formation.
      Intra-articular steroids may also suppress bone formation, however, the duration or
      relationship to a steroid dose has not been established. It is hypothesized that
      intra-articular steroids suppress bone formation transiently, returning to pretreatment
      levels within four weeks in subjects with osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral and nasal steroids may enhance osteoporosis by suppressing bone formation.
      Intra-articular steroids may also suppress bone formation, however, the duration or
      relationship to a steroid dose has not been established. It is hypothesized that
      intra-articular steroids suppress bone formation transiently, returning to pretreatment
      levels within four weeks in subjects with osteoarthritis. The purpose of the study is to
      determine if intra-articular steroids suppress markers of bone formation or resorption in
      osteoarthritis patients and whether these markers may be modified by Vitamin D or Dual-energy
      X-ray absorptiometry (DEXA) bone density status
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Osteocalcin</measure>
    <time_frame>Change from Baseline Visit to Day 28</time_frame>
    <description>Change in serum markers of bone formation (osteocalcin) from Day 0 to Day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)</measure>
    <time_frame>Change from Baseline Visit to Day 28</time_frame>
    <description>Outcome represents the mean change in serum biomarkers of bone breakdown (TRACP-5b) from baseline visit to day 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Testosterone</measure>
    <time_frame>Change from Baseline Visit to Day 28</time_frame>
    <description>Outcome represents the mean change in testosterone level from baseline visit to day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Cortisol</measure>
    <time_frame>Change from Baseline Visit to Day 28</time_frame>
    <description>Cortisol levels were measured over 28 days. Outcome represents mean change in cortisol level between baseline visit and day 28.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisone 80 mg and Lidocaine 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone 16 mg and Lidocaine 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Lidocaine 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone and Lidocaine</intervention_name>
    <description>Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone and Lidocaine</intervention_name>
    <description>Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and Lidocaine</intervention_name>
    <description>Placebo and lidocaine 20 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 40 years

          -  Male or postmenopausal female

          -  Diagnosis of knee osteoarthritis

          -  DEXA bone density done within the past 12 months

          -  Painful knee, visual analogue scale (VAS) &gt; 4 of (10=worst)

        Exclusion Criteria:

          -  Diabetes Mellitus Type I or II

          -  Systemic inflammatory illness

          -  Systemic infections which may be aggravated by steroid therapy

          -  No current or previous (&lt; 3 years) biphosphate therapy

          -  Previous knee replacement surgery

          -  No current or previous Parathyroid hormone (PTH) therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Lindsley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <results_first_submitted>October 5, 2016</results_first_submitted>
  <results_first_submitted_qc>October 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2016</results_first_posted>
  <last_update_submitted>October 5, 2016</last_update_submitted>
  <last_update_submitted_qc>October 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Herbert Lindsley, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis, intra articular steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Standard Dose</title>
          <description>Methylprednisolone and Lidocaine: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Low Dose</title>
          <description>Methylprednisolone and Lidocaine: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
        </group>
        <group group_id="P3">
          <title>Group 3 - Placebo</title>
          <description>Placebo and Lidocaine: Placebo and lidocaine 20 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 - Standard Dose</title>
          <description>Methylprednisolone and Lidocaine: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Low Dose</title>
          <description>Methylprednisolone and Lidocaine: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
        </group>
        <group group_id="B3">
          <title>Group 3 - Placebo</title>
          <description>Placebo and Lidocaine: Placebo and lidocaine 20 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Osteocalcin</title>
        <description>Change in serum markers of bone formation (osteocalcin) from Day 0 to Day 28.</description>
        <time_frame>Change from Baseline Visit to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Standard Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Low Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Placebo</title>
            <description>Placebo and Lidocaine: Placebo and lidocaine 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Osteocalcin</title>
          <description>Change in serum markers of bone formation (osteocalcin) from Day 0 to Day 28.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="2.24"/>
                    <measurement group_id="O2" value="-0.45" spread="2.90"/>
                    <measurement group_id="O3" value="-1.10" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)</title>
        <description>Outcome represents the mean change in serum biomarkers of bone breakdown (TRACP-5b) from baseline visit to day 28.</description>
        <time_frame>Change from Baseline Visit to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Standard Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Low Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Placebo</title>
            <description>Placebo and Lidocaine: Placebo and lidocaine 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b)</title>
          <description>Outcome represents the mean change in serum biomarkers of bone breakdown (TRACP-5b) from baseline visit to day 28.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.153" spread="0.457"/>
                    <measurement group_id="O2" value="-0.295" spread="0.472"/>
                    <measurement group_id="O3" value="-0.148" spread="0.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Testosterone</title>
        <description>Outcome represents the mean change in testosterone level from baseline visit to day 28.</description>
        <time_frame>Change from Baseline Visit to Day 28</time_frame>
        <population>Only males randomized to Group 1 - Standard Dose were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Standard Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Low Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Placebo</title>
            <description>Placebo and Lidocaine: Placebo and lidocaine 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Testosterone</title>
          <description>Outcome represents the mean change in testosterone level from baseline visit to day 28.</description>
          <population>Only males randomized to Group 1 - Standard Dose were included in this analysis.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Cortisol</title>
        <description>Cortisol levels were measured over 28 days. Outcome represents mean change in cortisol level between baseline visit and day 28.</description>
        <time_frame>Change from Baseline Visit to Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Standard Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Low Dose</title>
            <description>Methylprednisolone and Lidocaine: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 3 - Placebo</title>
            <description>Placebo and Lidocaine: Placebo and lidocaine 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Cortisol</title>
          <description>Cortisol levels were measured over 28 days. Outcome represents mean change in cortisol level between baseline visit and day 28.</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="5.69"/>
                    <measurement group_id="O2" value="0.65" spread="4.59"/>
                    <measurement group_id="O3" value="1.30" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Standard Dose</title>
          <description>Methylprednisolone and Lidocaine: Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Low Dose</title>
          <description>Methylprednisolone and Lidocaine: Methylprednisolone 16 mg intra-articular and lidocaine 20 mg</description>
        </group>
        <group group_id="E3">
          <title>Group 3 - Placebo</title>
          <description>Placebo and Lidocaine: Placebo and lidocaine 20 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Herbert Lindsley</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>(913) 588-3402</phone>
      <email>HLINDSLE@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

